Therapeutic applications of the carbonic anhydrase inhibitors

Therapy

Volumn 4, Issue 3, 2007, Pages 355-378

  Supuran, Claudiu T ^a  

^a Laboratorio di Chimica Bioinorganica   (Italy)

Author keywords

Anticancer drug; Antiglaucoma agent; Antiobesity agent; Carbonic anhydrase; Enzyme inhibitor; Isozyme; Sulfamate; Sulfamide; Sulfonamide; Tumor progression marker

Indexed keywords

ACETAZOLAMIDE; BENZOLAMIDE; BICARBONATE; BRINZOLAMIDE; CARBON DIOXIDE; CARBONATE DEHYDRATASE; CARBONATE DEHYDRATASE I; CARBONATE DEHYDRATASE II; CARBONATE DEHYDRATASE III; CARBONATE DEHYDRATASE INHIBITOR; CARBONATE DEHYDRATASE IV; CARBONATE DEHYDRATASE IX; CELECOXIB; DICLOFENAMIDE; DORZOLAMIDE; ELECTROLYTE; ETHOXZOLAMIDE; INDISULAM; ISOENZYME; METHAZOLAMIDE; PLACEBO; PROTON; SACCHARIN; SULFANILAMIDE; SULFONAMIDE; SULPIRIDE; TOPIRAMATE; UNINDEXED DRUG; VALDECOXIB; ZONISAMIDE;

ACID BASE BALANCE; ALTITUDE DISEASE; ANTINEOPLASTIC ACTIVITY; BITTER TASTE; BLURRED VISION; CANDIDA ALBICANS; CARCINOGENESIS; CLINICAL TRIAL; CRYPTOCOCCUS NEOFORMANS; DISEASE COURSE; DRUG DOSE INCREASE; DRUG INDICATION; DRUG MECHANISM; DRUG STRUCTURE; DRUG TARGETING; ELECTROLYTE TRANSPORT; ENZYME ACTIVITY; ENZYME STRUCTURE; EPILEPSY; EYE BURNING; EYE PAIN; GASTROINTESTINAL TUMOR; GENE TARGETING; GLAUCOMA; HELICOBACTER PYLORI; HUMAN; HYDRATION; ION TRANSPORT; MALIGNANT NEOPLASTIC DISEASE; MYCOBACTERIUM TUBERCULOSIS; NEUROLOGIC DISEASE; NONHUMAN; OBESITY; PLASMODIUM FALCIPARUM; PRURITUS; REVIEW; SIDE EFFECT; SOLID TUMOR; STRUCTURE ANALYSIS; UNSPECIFIED SIDE EFFECT;

EID: 34249083904     PISSN: 14750708     EISSN: 1744831X     Source Type: Journal    
DOI: 10.2217/14750708.4.3.355     Document Type: Review

References (120)

1. Supuran CT, Scozzafava A, Conway J: Carbonic Anhydrase: its Inhibitory and Activators. CRC Press, Boca Raton, FL, USA 1-363 (2004).
2. Supuran CT, Scozzafava A: Carbonic anhydrase inhibitors and their therapeutic potential. Expert Opin. Ther. Pat. 10, 575-600 (2000).
3. Supuran CT, Scozzafava A: Applications of carbonic anhydrase inhibitors and activators in therapy. Expert Opin. Ther. Pat. 12, 217-242 (2002).
4. Scozzafava A, Mastrolorenzo A, Supuran CT: Modulation of carbonic anhydrase activity and its applications in therapy. Expert Opin. Ther Pat. 14, 667-702 (2004).
5. Supuran CT, Scozzafava A, Casini A: Carbonic anhydrase inhibitors. Med. Res. Rev. 23, 146-189 (2003).
6. Supuran CT, Vullo D, Manole G, Casini A, Scozzafava A: Designing of novel carbonic anhydrase inhibitors and activators. Curr. Med Chem. Cardiovasc Hematol. Agents 2, 49-68 (2004).
7. Pastorekova S, Parkkila S, Pastorek J, Supuran CT: Carbonic anhydrases: current state of the art, therapeutic applications and future prospects. J. Enzyme Inhib. Med. Chem. 19, 199-229 (2004).
8. Supuran CT: Carbonic anhydrase inhibitors in the treatment and prophylaxis of obesity. Expert Opin. Ther Pat. 13, 1545-1550 (2003).
9. 2 hydration. J. Biol. Chem. 275, 5521-5526 (2000).
10. Strop P. Smith KS, Iverson TM, Ferry JG, Rees DC: Crystal structure of the "cab"-type β class carbonic anhydrase from the archaeon Methanobacterium thermoautotrophicum. J Biol. Chem. 276, 10299-10305 (2001).
11. Kimber MS, Pai EF: The active site architecture of Pisum sativum β-carbonic anhydrase is a mirror image of that of α-carbonic anhydrases. EMBO J. 19, 1407-1418 (2000).
12. Iverson TM, Alber BE, Kisker C, Ferry JG, Rees DC: A closer look at the active site of γ-class carbonic anhydrases: high-resolution crystallographic studies of the carbonic anhydrase from Methanosarcina thermophila. Biochemistry 39, 9222-9231 (2000).
13. Cox EH, McLendon GL, Morel FM et al.: The active site structure of Thalassiosira weissflogii carbonic anhydrase 1. Biochemistry 39, 12128-12130 (2000).
14. Lane TW. Morel FM: A biological function for cadmium in marine diatoms. Proc. Natl Acad. Sci. USA 97, 4627-4631 (2000).
15. Abbate F, Supuran CT, Scozzafava A, Orioli P, Stubbs MT, Klebe G: The sulfonamide group as an ideal anchor for the design of potent human carbonic anhydrase inhibitors: role of hydrogen-bonding networks in ligand binding and drug design. J. Med. Chem. 45, 3583-3587 (2002).
16. Ferraroni M. Briganti F, Chegwidden WR et al.: Structure of the human carbonic anhydrase (hCA) isoenzyme I Michigan 1 variant in the absence and in the presence of exogenous zinc ions: the first CA binding two zinc ions. Biochemistry 41, 6237-6244 (2001).
17. Kim CY, Chandra PP, Jain A, Christianson DW: Fluoroaromatic-fluoroaromatic interactions between inhibitors bound in the crystal lattice of human carbonic anhydrase II. J. Am. Chem. Soc. 123, 9620-9627 (2001).
18. Whittington DA, Waheed A, Ulmasov B et al.: Crystal structure of the dimeric extracellular domain of human carbonic anhydrase XII, a bitopic membrane protein overexpressed in certain cancer tumor cells. Proc. Natl Acad. Sci. USA 98, 9545-9550 (2001).
19. Stams T, Nair SK, Okuyama T, Waheed A, Sly WS, Christianson DW. Crystal structure of the secretory form of membran-associated human carbonic anhydrase IV at 2.8 Å resolution. Proc. Natl Acad. Sci. USA 93, 13589-13594 (1996).
20. Lindahl M, Vidgren J, Eriksson E et al.: Crystallographic studies of carbonic anhydrase inhibition. In: Carbonic Anhydrase. Botrè F, Gros G, Storey BT (Eds). VCH, Weinheim, Germany 111-118 (1991).
21. Alterio, V, Vitale RM, Monti SM et al.: Carbonic anhydrase inhibitors: x-ray and molecular modeling study for the interaction of a fluorescent antitumor sulfonamide with isozyme II and IX. J. Am. Chem. Soc. 128, 8329-8335 (2006).
22. De Simone G, Di Fiore A, Menchise V et al.: Carbonic anhydrase inhibitors. Zonisamide is an effective inhibitor of the cytosolic isozyme II and mitochondrial isozyme V: solution and x-ray crystallographic studies. Bioorg. Med. Chem, Lett. 15, 2315-2320 (2005).
23. Di Fiore A, Pedone C, D'Ambrosio K, Scozzafava A, De Simone G, Supuran CT: Carbonic anhydrase inhibitors: valdecoxib binds to a different active site region of the human isoform II as compared to the structurally related cycloaxygenase II "selective" inhibitor celecoxib. Bioorg. Med. Chem. Lett. 16, 437-442 (2006).
24. Menchise V, De Simone G, Alterio, V et al.: Carbonic anhydrase inhibitors: stacking with Phe131 determines active site binding region of Inhibitors as exemplified by the x-ray crystal structure of a membrane-impermeant antitumor sulfonamide complexed with isozyme II. J. Med. Chem. 48, 5721-5727 (2005).
25. Krungkrai SR, Suraveratum N, Rochanakij S, Krungkrai J: Characterisation of carbonic anhydrase in Plasmodium falciparum. Int. J. Parasitol. 31, 661-668 (2001).
26. Supuran CT, Scozzafava A, Casini A: Development of sulfonamide carbonic anhydrase inhibitors. In: Carbonic Anhydrase: its Inhibitors and Activators. Supuran CT; Scozzafava A, Conway J (Eds). CRC Press, Boca Raton, FL, USA 67-147 (2004).
27. Scozzafava A, Mastrolorenzo A, Supuran CT: Carbonic anhydrase inhibitors and activators and their use in therapy. Expert Opin. Ther. Pat. 16, 1627-1644, (2006).
28. Supuran CT: Carbonic anhydrases: catalytic and inhibition mechanisms, distribution and physiological roles. In: Carbonic Anhydrase: its Inhibitors and Activators. Supuran CT; Scozzafava A, Conway J (Eds). CRC Press, Boca Raton, FL, USA 1-23 (2004).
29. Scozzafava A, Briganti F, Ilies MA, Supuran CT: Carbonic anhydrase Inhibitors: synthesis of membrane-impermeant low molecular weight sulfonamides possessing in vivo selectivity for the membrane-bound versus cytosolic isozymes. J. Med. Chem. 43, 292-300 (2000).
30. Scozzafava A, Supuran CT: Carbonic anhydrase inhibitors: synthesis of N-morpholylthiocarbonylsulfenylamino aromatic/heterocyclic sulfonamides and their interaction with isozymes I, II and IV. Bioorg. Med. Chem. Lett. 10, 1117-1120 (2000).
31. Barbolu M, Supuran CT, Menabuoni L et al.: Carbonic anhydrase inhibitors. Synthesis of topically effective intraocular pressure lowering agents derived from 5-(O-aminoalkylcarboxamido)-1,3,4-thiadiazole2-sulfonamide. J. Enzyme Inhib. 15, 23-46 (2000).
32. Briganti F, Tilli S, Mincione G, Mincione F, Menabuoni L, Supuran CT: Carbonic anhydrase inhibitors. Metal complexes of 5-(2-chlorophenyl)-1,3,4-thiadiazole-2-sulfonamide with topical intraocular pressure lowering properties: the influence of metal ions upon the pharmacological activity. J. Enzyme Inhib. 15, 185-200 (2000).
33. Supuran CT, Scozzafava A, Ilies MA, Briganti F: Carbonic anhydrase inhibitors: synthesis of sulfonamides incorporating 2,4,6-trisubstituted-pyridinium-ethylcarboxamido moieties possessing membrane-impermeability and in vivo selectivity for the membrane-bound (CA IV) versus the cytosolic (CA I and CA II) isozymes. J. Enzyme Inhib. 15, 381-401 (2000).
34. Ilies M, Supuran CT Scozzafava A et al.: Carbonic anhydrase inhibitors: sulfonamides incorporating furan-, thiophene- and pyrrole-carboxamido groups possess strong topical intraocular pressure lowering properties as aqueous suspensions. Bioorg Med. Chem. 8, 2145-2455 (2000).
35. Clare BW, Supuran CT: Carbonic anhydrase inhibitors. Part 86. A QSAR study on some sulfonamide drugs which lower intra-ocular pressure, using the ACE non-linear statistical method. Eur. J. Med. Chem. 35, 859-865 (2000).
36. Scozzafava A, Banciu MD, Popescu A, Supuran CT: Carbonic anhydrase inhibitors: inhibition of isozymes I, II and IV by sulfamide and sulfamic acid derivatives. J. Enzyme Inhib. 15, 443-453 (2000).
37. Scozzafava A, Menabuoni L, Mincione F, Briganti F, Mincione G, Supuran CT: Carbonic anhydrase inhibitors: perfluoroalkyl/aryl-substituted derivatives of aromatic/heterocyclic sulfonamides as topical intraocular pressure-lowering agents with prolonged duration of action. J. Med. Chem. 43, 4542-4551 (2000).
38. Casini A, Scozzafava A, Mincione F, Menabuoni L, Ilies MA, Supuran CT: Carbonic anhydrase inhibitors: water-soluble 4-sulfamoylphenylthioureas as topical intraocular pressure-lowering agents with long-lasting effects. J. Med. Chem. 43, 4884-4892 (2000).
39. Mastrolorenzo A, Scozzafava A, Supuran CT: Antifungal activity of Ag(I) and Zn(II) complexes of aminobenzolamide (5-sulfanilylamido-1,3,4-thiadiazole-2-sulfonamide) derivatives. J. Enzyme Inhib. 15, 517-531 (2000).
40. Scozzafava A, Banciu MD, Popescu A, Supuran CT: Carbonic anhydrase inhibitors: synthesis of Schiff bases of hydroxybenzaldehydes with aromatic sulfonamides and their reactions with arylsulfonyl isocyanates. J. Enzyme Inhib. 15, 533-546 (2000).
41. Supuran CT, Scozzafava A: Carbonic anhydrase inhibitors: aromatic sulfonamides and disulfonamides act as efficient tumor growth inhibitors. J. Enzyme Inhib. 15, 597-610 (2000).
42. Supuran CT, Scozzafava A: Carbonic anhydrase inhibitors - Part 94. 1,3,4- thiadiazole-2-sulfonamidederivatives as antitumor agents? Eur. J. Med. Chem. 35, 867-874 (2000).
43. Supuran CT, Briganti F, Tilli S, Chegwidden WR, Scozzafava A: Carbonic anhydrase inhibitors: sulfonamides as antitumor agents? Bioorg. Med. Chem. 9, 703-714 (2001).
44. Scozzafava A, Menabuoni L, Mincione F, Minclone G, Supuran CT: Carbonic anhydrase inhibitors: synthesis of sulfonamides incorporating DTPA tails and of their zinc complexes with powerful topical antiglaucoma properties. Bioorg. Med. Chem. Lett. 11, 575-582 (2001).
45. Casini A, Mincione F, Ilies MA, Menabuoni L, Scozzafava A, Supuran CT: Carbonic anhydrase inhibitors: synthesis and inhibition against isozymes I, II and IV of topically acting antiglaucoma sulfonamides incorporating cis-5- norbornene-endo-3-carboxy-2-carboxamido moieties. J. Enzyme Inhib. 16, 113-123 (2001).
46. Chazalette C, Riviere-Baudet M, Scozzafava A, Abbate F, Ben Maarouf Z, Supuran CT: Carbonic anhydrase Inhibitors, interaction of boron derivatives with isozymes I and II: a new binding site for hydrophobic inhibitors at the entrance of the active site as shown by docking studies. J. Enzyme Inhib. 16, 125-133 (2001).
47. Mincione F, Starnotti M, Menabuoni L, Scozzafava A, Casini A, Supuran CT: Carbonic anhydrase inhibitors: 4-sulfamoyl-benzenecarboxamides and 4-chloro-3-sulfamoyl-benzenecarboxamides with strong topical antiglaucoma properties. Bioorg. Med. Chem. Lett. 11, 1787-1791 (2001).
48. Supuran CT, Clare BW: Orbital symmetry in QSAR: some Schiff's base inhibitors of carbonic anhydrase. SAR QSAR Environ. Res. 12, 17-29 (2001).
49. Scozzafava A, Supuran CT: Carbonic anhydrase and matrix metalloproteinase inhibitors: sulfonylated amino acid hydroxamates with MMP inhibitory properties act as efficient inhibitors of CA isozymes I, II, and IV, and N-hydroxysulfonamides inhibit both these zinc enzymes. J. Med. Chem. 43, 3677-3687 (2000).
50. Abbate F, Casini A, Owa T, Scozzafava A, Supuran CT: Carbonic anhydrase inhibitors: E7070, a sulfonamide anticancer agent, potently inhibits cytosolic isozymes I and II, and transmembrane, tumor-associated isozyme IX Bioorg. Med. Chem. Lett. 14, 217-223 (2004).
51. Casini A, Antel J, Abbate F et al.: Carbonic anhydrase inhibitors: SAR and x-ray crystallographic study for the interaction of sugar sulfamates/sulfamides with isozymes I, II and IV. Bioorg. Med. Chem. Lett. 13, 841-845 (2003).
52. Abbate F, Coetzee A, Casini A, Ciattini S, Scozzafava A, Supuran CT: Carbonic anhydrase inhibitors: x-ray crystallographic structure of the adduct of human isozyme II with the antipsychotic drug sulpiride. Bioorg. Med. Chem. Lett. 14, 337-341 (2004).
53. Lloyd MD, Pederick RL, Natesh R et al.: Crystal structure of human carbonic anhydrase II at 1.95 Å resolution in complex with 667-coumate, a novel anti-cancer agent. Biochem. J. 385, 715-720 (2005).
54. Abbate F, Winum JY, Potter BV et al.: Carbonic anhydrase inhibitors: x-ray crystallographic structure of the adduct of human isozyme II with EMATE, a dual inhibitor of carbonic anhydrases and steroid sulfatase. Bioorg. Med. Chem. Lett. 14, 231-234 (2004).
55. Weber A, Casini A, Heine A et al.: Unexpected nanomolar inhibition of carbonic anhydrase by COX-2-selective celecoxib: new pharmacological opportunities due to related binding site recognition. J. Med. Chem. 47, 550-557 (2004).
56. Köhler K, Hillebrecht A, Innocenti A, Heine A, Supuran CT, Kiebe G: Saccharin, a potent inhibitor of carbonic anhydrases. Science (2007) (In Press).
57. Seong GJ, Lee SC, Lee JH, Chu YK, Hong YJ: Comparisons of intraocular-pressure- lowering efficacy and side effects of 2% dorzolamide and 1% brinzolamide. Ophthalmologica 215, 188-191 (2001).
58. Ormrod D, McClellan K: Topical dorzolamide 2%/timolol 0.5%: a review of its use in the treatment of open-angle glaucoma. Drugs Aging 17, 477-496 (2000).
59. Susanna R Jr, Nicolela MT, Oga E: Additive effect of latanoprost to the combination of timolol and dorzolamide. J. Glaucoma 9, 183-186 (2000).
60. Gelatt KN, MacKay EO: Changes in intraocular pressure associated with topical dorzolamide and oral methazolamide in glaucomatous dogs. Vet. Ophthalmol. 4, 61-67 (2001).
61. Michaud JE, Friren B; The International Brinzolamide Adjunctive Study Group: Comparison of topical brinzolamide 1% and dorzolamide 2% eye drops given twice daily in addition to timolol 0.5% in patients with primary open-angle glaucoma or ocular hypertension. Am. J. Ophthalmol. 132, 235-243 (2001).
62. Wolfensberger TJ: The role of carbonic anhydrase inhibitors in the management of macular edema. Doc. Ophthalmol. 97, 387-397 (1999).
63. Gao BB, Clermont A, Rook S et al.: Extracellular carbonic anhydrase mediates hemorrhagic retinal and cerebral vascular permeability through prekallikrein activation. Nat. Med. 13, 181-188 (2007).
64. Pastorekova S, Pastorek J: Cancer-related carbonic anhydrase isozymes and their inhibition. In: Carbonic Anhydrase: its Inhibitors and Activators. Supuran CT, Scozzafava A, Conway J (Eds). CRC Press, Boca Raton, FL, USA 253-280 (2004).
65. Thiry A, Dogne JM, Masereel B, Supuran CT: Targeting tumor-associated carbonic anhydrase IX in cancer therapy. Trends Pharmacol. Sci. 27, 566-573 (2006).
66. Svastova E, Hulikova A, Rafajova M et al.: Hypoxia activates the capacity of tumor-associated carbonic anhydrase IX to acidify extracellular pH. FEBS Lett. 577, 439-445 (2004).
67. Cecchi A, Hulikova A, Pastorek J et al.: Carbonic anhydrase inhibitors. Design of fluorescent sulfonamides as probes of tumor-associated carbonic anhydrase IX that inhibit isozyme IX-mediated acidification of hypoxic tumors. J. Med. Chem., 48, 4834-4841 (2005).
68. Casey JR, Morgan PE, Vullo D, Scozzafava A, Mastrolorenzo A, Supuran CT: Carbonic anhydrase inhibitors. Design of selective, membrane-impermeant inhibitors targeting the human tumor-associated isozyme IX. J. Med. Chem. 47, 2337-2347 (2004).
69. Vullo D, Steffansen B, Brodin B, Supuran CT, Scozzafava A, Nielsen CU: Carbonic anhydrase inhibitors: transepithelial transport of thioureido sulfonamide inhibitors of the cancer-associated isozyme IX is dependent on efflux transporters. Bioorg. Med. Chem. 14, 2418-2427 (2006).
70. Parkkila S, Rajaniemi H, Parkkila AK et al.: Carbonic anhydrase inhibitor suppresses invasion of renal cancer cells in vitro. Proc. Natl Acad. Sci. USA 97, 2220-2224 (2000).
71. Saarnio J, Parkkila S, Parkkila AK et al.: Transmembrane carbonic anhydrase, MN/CA IX, is a potential biomarker for biliary tumours. J. Hepatol. 35, 643-649 (2001).
72. Giatromanolaki A, Koukourakis MI, Sivridis E et al.: Expression of hypoxia-inducible carbonic anhydrase-9 relates to angiogenic pathways and independently to poor outcome in non-small cell lung cancer. Cancer Res. 61, 7992-7998 (2001).
73. Chia SK, Wykoff CC, Watson PH et al.: Prognostic significance of a novel hypoxia-regulated marker, carbonic anhydrase IX, in invasive breast carcinoma. J. Clin. Oncol. 19, 3660-3668 (2001).
74. Loncaster JA, Harris AL, Davidson SE et al.: Carbonic anhydrase (CA IX) expression, a potential new intrinsic marker of hypoxia: correlations with tumor oxygen measurements and prognosis in locally advanced carcinoma of the cervix. Cancer Res. 61, 6394-6399 (2001).
75. Wykoff CC, Beasley N, Watson PH et al.: Expression of the hypoxia-inducible and tumor-associated carbonic anhydrases in ductal carcinoma in situ of the breast. Am. J. Pathol. 158, 1011-1019 (2001).
76. Beasley NJ, Wykoff CC, Watson PH et al.: Carbonic anhydrase IX, an endogenous hypoxia marker, expression in head and neck squamous cell carcinoma and its relationship to hypoxia, necrosis, and microvessel density. Cancer Res. 61, 5262-5267 (2001).
77. Kivela AJ, Saarnio J, Karttunen TJ et al.: Differential expression of cytoplasmic carbonic anhydrases, CA I and II, and membrane-associated isozymes, CA IX and XII, in normal mucosa of large intestine and in colorectal tumors. Dig. Dis. Sci. 46, 2179-2186 (2001).
78. Parkkila S, Parkkila AK, Saarnio J et al.: Expression of the membrane-associated carbonic anhydrase isozyme XII in the human kidney and renal tumors. J. Histochem. Cytochem. 48, 1601-1608 (2000).
79. Sari R, Camci C, Kutlu R, Totan Y, Sevinc A, Buyukberber S: The efficacy of acetazolamide on visual functions in a patient with choroid metastasis of breast carcinoma. Int. J. Clin. Pract. 55, 488-490 (2001).
80. Spencer IM, Hargreaves I, Chegwidden WR. Effect of the carbonic anhydrase inhibitor acetazolamide on lipid synthesis in the locust. Biochem. Soc. Trans. 16, 973-974 (1988).
81. Chegwidden WR, Spencer IM. Carbonic anhydrase provides bicarbonate for de novo lipogenesis in the locus. Comp. Biochem. Physiol. 115B, 247-254 (1996).
82. Chegwidden WR, Dodgson SJ, Spencer IM: The roles of carbonic anhydrase in metabolism, cell growth and cancer in animals. In: The Carbonic Anhydrases - New Horizons. Chegwidden WR, Edwards Y, Carter N (Eds). Birkhäuser Verlag, Basel, Switzerland 343-363 (2000).
83. Lynch CJ, Fox H, Hazen SA, Stanley BA, Dodgson SJ, Lanoue KF: Role of hepatic carbonic anhydrase in de novo lipogenesis. Biochem. J. 310, 197-202 (1995).
84. Hazen SA, Waheed A, Sly WS, Lanoue KF, Lynch CJ: Differentiation-dependent expression of CA V and the role of carbonic anhydrase isozymes in pyruvate carboxylation in adipocytes. FASEB J. 10, 481-490 (1996).
85. Atwood PV: The structure and mechanism of action of pyruvate carboxylase. Int. J. Biochem. Cell Biol. 27, 231-249 (1995).
86. Alldred JB, Reilly KE: Short-term regulation of acetyl CoA carboxylase in tissues of higher animals. Prog. Lipid Res. 35, 371-385 (1997).
87. Forster RE, Dodgson SJ: Membrane transport and provision of substrates for carbonic anhydrase in vertebrates. In: The Carbonic Anhydrases - New Horizons. Chegwidden WR, Edwards Y, Carter N (Eds). Birkhäuser Verlag, Basel, Switzerland 263-280 (2000).
88. Parkkila S: An overview of the distribution and function of carbonic anhydrase isozymes in mammals. In: The Carbonic Anhydrases - New Horizons. Chegwidden WR, Edwards Y, Carter N (Eds). Birkhäuser Verlag, Basel, Switzerland 79-94 (2000).
89. Parkkila S, Parkkila AK, Kivelä J: Role of carbonic anhydrase and its inhibitors in biological science related to gastroenterology, neurology and nephrology, In: Carbonic Anhydrase: its Inhibitors and Activators. Supuran CT, Scozzafava A, Conway J (Eds). CRC Press, Boca Raton, FL, USA 283-301 (2004).
90. Gordon A, Price LH: Mood stabilization and weight loss with topiramate. Am. J. Psychiatry 156, 968-969 (1999).
91. Picard F, Deshaies Y, Lalonde J, Samson P, Richard D: Topiramate reduces energy and fat gains in lean (Fa/?) and obese (fa/fa) Zucker rats. Obesity Res. 8, 656-663 (2000).
92. Vullo D, Franchi M, Gallori E, Antel J, Scozzafava A, Supuran CT: Carbonic anhydrase inhibitors. Inhibition of mitochondrial isozyme V with aromatic and heterocyclic sulfonamides. J. Med. Cbem. 47, 1272-1279 (2004).
93. Nishimori I, Vullo D, Innocenti A, Scozzafava A, Mastrolorenzo A, Supuran CT: Carbonic anhydrase inhibitors. The mitochondrial isozyme VB as a new target for sulfonamide and sulfamate inhibitors. J. Med. Chem. 48, 7860-7866 (2005).
94. Albaugh VL, Henry CR, Bello NT et al.: Hormonal and metabolic effects of olanzapine and clozapine related to body weight in rodents. Obesity 14, 36-51 (2006).
95. Lin YH, Liu CY, Hsiao MC: Management of atypical antipsychotic-induced weight gain in schizophrenic patients with topiramate. Psychiatry Clin. Neurosci. 59, 613-615 (2005).
96. Zareba G: Zonisamide: review of its use in epilepsy therapy. Drug Today (Barc.) 41, 589-597 (2005).
97. Canitano R: Clinical experience with Topiramate to counteract neuroleptic induced weight gain in 10 individuals with autistic spectrum disorders. Brain Dev. 27, 228-232 (2005).
98. Kim CS: Zonisamide effective for weight loss in women. J. Fam. Pract. 52, 600-601 (2003).
99. Gadde KM, Franciscy DM, Wagner HR 2nd, Krishnan KR: Zonisamide for weight loss in obese adults: a randomized controlled trial. JAMA 289, 1820-1825 (2003).
100. Tawil R, McDermott MP, Brown R Jr et al.: Randomized trials of dichlorphenamide in the periodic paralyses. Working Group on Periodic Paralysis. Ann. Neurol. 47, 46-53 (2000).
101. Koller WC, Hristova A, Brin M: Pharmacologic treatment of essential tremor. Neurology 54(Suppl 4), S30-S38 (2000).
102. Parkkila S, Parkkila AK, Rajaniemi H et al.: Expression of membrane-associated carbonic anhydrase XIV on neurons and axons in mouse and human brain. Proc. Natl Acad Sci. USA 98, 1918-1923 (2001).
103. Taki K, Oogushi K, Hirahara K, Gai X, Nagashima F, Tozuka K: Preferential acetazolamide-induced vasodilation based on vessel size and organ: confirmation of peripheral vasodilation with use of colored microspheres. Angiology 52, 483-488 (2001).
104. Komai M, Goto T, Suzuki H, Takeda T, Furukawa Y: Zinc deficiency and taste dysfunction; contribution of carbonic anhydrase, a zinc-metalloenzyme, to normal taste sensation. Biofactors 12, 65-70 (2000).
105. Karhumaa P, Leinonen J, Parkkila S, Kaunisto K, Tapanainen J, Rajaniemi H: The identification of secreted carbonic anhydrase VI as a constitutive glycoprotein of human and rat milk. Proc. Natl Acad. Sci. USA 98, 11604-11608 (2001).
106. Nishimori I, Minakuchi T, Onishi S, Vullo D, Scozzafava A, Supuran CT: Carbonic anhydrase inhibitors. DNA cloning, characterization, and inhibition studies of the human secretory isoform VI, a new target for sulfonamide and sulfamate inhibitors. J. Med. Chem. 50, 381-388 (2007).
107. Frulloni L, Bovo P, Brunelli S et al.: Elevated serum levels of antibodies to carbonic anhydrase I and II in patients with chronic pancreatitis. Pancreas 20, 382-388 (2000).
108. Reiss WG, Oles KS: Acetazolamide in the treatment of seizures. Ann. Pharmacother. 30, 514-519 (1996).
109. Katayama F, Miura H, Takanashi S: Long-term effectiveness and side effects of acetazolamide as an adjunct to other anticonvulsants in the treatment of refractory epilepsies. Brain Dev. 24, 150-154 (2002).
110. Parkkila S, Parkkila AK, Kivela J: Role of carbonic anhydrase and its inhibitors in gastroenterology, neurology and nephrology. In: Carbonic Anhydrase: its Inhibitors and Activators. Supuran CT, Scozzafava A, Conway J (Eds). CRC Press, Boca Raton, FL, USA 283-301 (2004).
111. Leppik IE: Zonisamide: chemistry, mechanism of action, and pharmacokinetics. Seizure 13(Suppl. 1), S5-9 (2004).
112. Herrero AI, Del Olmo N, Gonzalez-Escalada JR, Solis JM: Two new actions of topiramate: inhibition of depolarizing GABA(A)-mediated responses and activation of a potassium conductance. Neuropharmacology 42, 210-220 (2002).
113. Ilies MA, Masereel B, Rolin S et al.: Carbonic anhydrase inhibitors: aromatic and heterocyclic sulfonamides incorporating adamantyl moieties with strong anticonvulsant activity. Bioorg. Med. Chem. Lett, 12, 2717-2726 (2004).
114. 3-exchange. Br. J. Pharmacol. 142, 831-842 (2004).
115. Vullo D, Voipio J, Innocenti A et al.: Carbonic anhydrase inhibitors. Inhibition of the human cytosolic isozyme VII with aromatic and heterocyclic sulfonamides. Bioorg. Med. Chem. Lett. 15, 971-976 (2005).
116. Pasternack M, Voipio, J, Kaila K: Intracellular carbonic anhydrase activity and its role in GABA-incluced acidosis in isolated rat hippocampal pyramidal neurones. Acta Physiol. Scand. 148, 229-231 (1993).
117. Aribi AM, Stringer JL: Effects of antiepileptic drugs on axtracellular pH regulation in the hippocampal CA1 region in vivo. Epilepsy Res. 49, 143-151 (2002).
118. Bernhard WN, Schalik LM, Delaney PA, Bernhard TM, Barnas GM: Acetazolamide plus low-dose dexamethasone is better than acetazolamide alone to ameliorate symptoms of acute mountain sickness. Aviat. Space Environ. Med. 69, 883-886 (1998).
119. Bradwell AR, Wright AD, Winterborn M, Imray C: Acetazolamide and high altitude disease. Int. J. Sports Med. 13, 63-64 (1992).
120. Porcelli MJ, Gugelchuk GM: A trek to the top: a review of acute mountain sickness. J. Am. Osteopath. Assoc. 95, 718-720 (1995).